Sinovac Biotech Files 6-K Report
Ticker: SVA · Form: 6-K · Filed: Jan 16, 2025
Sentiment: neutral
Topics: sec-filing, compliance, foreign-private-issuer
TL;DR
Sinovac Biotech filed a routine 6-K, no new info.
AI Summary
Sinovac Biotech Ltd. filed a Form 6-K report on January 16, 2025, for the month of January 2025. The report is a routine filing for a foreign private issuer and does not contain specific financial or operational updates beyond its submission status. The company is based in Beijing, People's Republic of China.
Why It Matters
This filing indicates ongoing compliance with SEC reporting requirements for foreign private issuers. It does not provide new material information about the company's performance or strategic direction.
Risk Assessment
Risk Level: low — This is a standard procedural filing (6-K) and does not contain new material information that would typically impact risk.
Key Numbers
- 20250116 — Report Date (Date the report was filed and pertains to.)
Key Players & Entities
- Sinovac Biotech Ltd. (company) — Filer of the report
- Nan Wang (person) — Signatory for the filing
- 001-32371 (dollar_amount) — SEC File Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers which provides information that the issuer would be required to disclose to its home country security holders, or that it makes public in its home country. It is filed periodically for the month it covers.
What specific operational or financial information is included in this 6-K filing?
This particular 6-K filing does not appear to contain specific operational or financial updates; it serves as a notification of the company's reporting status.
When was this Form 6-K filed?
This Form 6-K was filed on January 16, 2025.
What is the SEC file number for Sinovac Biotech Ltd.?
The SEC file number for Sinovac Biotech Ltd. is 001-32371.
Where is Sinovac Biotech Ltd. headquartered?
Sinovac Biotech Ltd. is headquartered in Beijing, People's Republic of China.
Filing Stats: 141 words · 1 min read · ~1 pages · Grade level 13.2 · Accepted 2025-01-16 08:48:28
Filing Documents
- tm253535d1_6k.htm (6-K) — 9KB
- tm253535d1_ex99-1.htm (EX-99.1) — 6KB
- 0001104659-25-003961.txt ( ) — 16KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 00 1-32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 100085, People’s Republic of China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SINOVAC BIOTECH LTD. By: /s/ Nan Wang Name: Nan Wang Title: Chief Financial Officer Date: January 16, 2025 Exhibit Index Exhibit 99.1 Press Release